PA8574201A1 - NEW COMBINATION - Google Patents

NEW COMBINATION

Info

Publication number
PA8574201A1
PA8574201A1 PA20038574201A PA8574201A PA8574201A1 PA 8574201 A1 PA8574201 A1 PA 8574201A1 PA 20038574201 A PA20038574201 A PA 20038574201A PA 8574201 A PA8574201 A PA 8574201A PA 8574201 A1 PA8574201 A1 PA 8574201A1
Authority
PA
Panama
Prior art keywords
new combination
inhibitor
phosphodesterase
gmpc
pde5
Prior art date
Application number
PA20038574201A
Other languages
Spanish (es)
Inventor
Bernadette Hughes
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8574201A1 publication Critical patent/PA8574201A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LAS COMBINACIONES QUE COMPRENDEN A) UN INHIBIDOR DE FOSFODIESTERASA DE TIPO 5 (PDE5) ESPECIFICA DE MONOFOSFATO DE GUANOSINA CICLICO (GMPC) Y B) UN INHIBIDOR DE ENZIMA DE CONVERSION DE ANGIOTENSINA (ACE) SON UTILES PARA TRATAR LA HIPERTENSION.THE COMBINATIONS THAT INCLUDE A) A TYPE 5 PHOSPHODESTERASE INHIBITOR (PDE5) SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND B) AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR (ACE) ARE USEFUL TO TREAT THE.

PA20038574201A 2002-05-23 2003-05-22 NEW COMBINATION PA8574201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
PA8574201A1 true PA8574201A1 (en) 2003-12-19

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038574201A PA8574201A1 (en) 2002-05-23 2003-05-22 NEW COMBINATION

Country Status (18)

Country Link
EP (1) EP1506015A2 (en)
JP (1) JP2005529927A (en)
KR (1) KR20050004195A (en)
CN (1) CN1655820A (en)
AR (1) AR040090A1 (en)
AU (1) AU2003223071A1 (en)
BR (1) BR0311191A (en)
CA (1) CA2485984A1 (en)
IL (1) IL164975A0 (en)
MX (1) MXPA04010951A (en)
NO (1) NO20045517L (en)
PA (1) PA8574201A1 (en)
PE (1) PE20040514A1 (en)
PL (1) PL374198A1 (en)
RU (1) RU2004133973A (en)
TW (1) TW200407153A (en)
UY (1) UY27816A1 (en)
WO (1) WO2003099194A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (en) * 2006-06-13 2012-12-07 Bioprojet Soc Civ USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
CA2661483A1 (en) * 2006-08-24 2008-02-28 Surface Logix, Inc. Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN113181110A (en) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 Liquid aqueous pharmaceutical composition containing preserved etherified cyclodextrin derivatives
BR112016011111B1 (en) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
UA46166C2 (en) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-Phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors, methods for their preparation and medicaments based on them
AU7547900A (en) * 1999-10-11 2001-04-23 Pfizer Inc. 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
IL164975A0 (en) 2005-12-18
EP1506015A2 (en) 2005-02-16
UY27816A1 (en) 2003-12-31
NO20045517L (en) 2004-12-17
TW200407153A (en) 2004-05-16
CA2485984A1 (en) 2003-12-04
RU2004133973A (en) 2005-09-10
JP2005529927A (en) 2005-10-06
PL374198A1 (en) 2005-10-03
AR040090A1 (en) 2005-03-16
KR20050004195A (en) 2005-01-12
BR0311191A (en) 2005-03-01
CN1655820A (en) 2005-08-17
PE20040514A1 (en) 2004-08-24
MXPA04010951A (en) 2005-06-08
WO2003099194A3 (en) 2004-06-03
AU2003223071A1 (en) 2003-12-12
WO2003099194A2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
HN2003000227A (en) KINASE INHIBITORS
BR0108485A (en) Azaindole antiviral derivatives
PA8574201A1 (en) NEW COMBINATION
ECSP056173A (en) COMPOSITION THAT INCLUDES A PDE4 INHIBITOR AND A PDE5 INHIBITOR
IL162728A0 (en) Methods of inducing differentiationin stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem c
ECSP034519A (en) XANTINA PHOSPHODIESTERASE V INHIBITORS
NO20054369L (en) Use of an IBAT inhibitor for the treatment and prophylaxis of constipation
UY27729A1 (en) QUINASE INHIBITORS.
CY1105390T1 (en) THERAPEUTIC MANAGEMENT OF PULMONARY HYPERTENSION
DK1073658T3 (en) Pyrazolopyrimidinone cGMP PDE5 Inhibitors for the Treatment of Sexual Disorder
NO20001583D0 (en) Stimulation of hematopoietic cells in vitro
DE60134692D1 (en) Lighting arrangement for keyboards and the dynamic or individual illumination of the keys and methods for their use
DK1583541T3 (en) Compounds and Methods to Increase Neurogenesis
ATE453707T1 (en) METHOD FOR ISOLATION OF MESENCHYMAL STEM CELLS OF THE HAIR FOLLICLE
HN2001000217A (en) NEW TIADIAZOLS AND OXADIAZOLS AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE - 7
ES2191830T3 (en) THROMBIN INHIBITORS.
HN2003000208A (en) PERFECTED STRUCTURE OF WATERPROOF AND TRANSPIRANT FLOOR FOR SHOES
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
NO20050400L (en) New combination preparation
UY27813A1 (en) PEPTIDE-DISFORMILASE INHIBITORS
DE69835288D1 (en) COMBINATION THERAPY FOR MODULATING THE HUMAN SEXUAL REACTION
EP1546182A4 (en) Compositions and methods for the diagnosis and treatment of tumor
HN2003000071A (en) COMBINATIONS OF A BINDING ALFA-2-DELTA WITH A SELECTIVE INHIBITOR OF THE CYCLOOXYGENASA-2
DE69625230D1 (en) thrombin inhibitors
FI20021286A0 (en) Arrangement and method of generating electrical power and power supply